Skip to main content
Reproductive Biology and Endocrinology : RB&E logoLink to Reproductive Biology and Endocrinology : RB&E
. 2014 Sep 23;12:92. doi: 10.1186/1477-7827-12-92

Endometrial gene expression reveals compromised progesterone signaling in women refractory to embryo implantation

Alejandro Tapia-Pizarro 1,, Paula Figueroa 2, Julio Brito 2, Juan Carlos Marín 3, David J Munroe 4, Horacio B Croxatto 5
PMCID: PMC4181418  PMID: 25248672

Abstract

Background

Endometrial function is essential for embryo implantation. The aim of this study was to analyze gene expression profiles from individual endometrial samples obtained from women with repeated implantation failure after IVF in oocyte donation programs.

Methods

Seventeen volunteers were recruited: women who had previously participated as recipients in oocyte donation cycles and repeatedly exhibited implantation failure (Group A, study group, n = 5) or had at least one successful cycle (Group B, control group, n = 6) and spontaneously fertile women (Group C, normal fertility group, n = 6). An endometrial cycle was induced with exogenous estradiol (E2) and progesterone (P) and an endometrial sample was collected on the seventh day of P treatment.

Results

Transcriptome analysis showed 82 genes with consistent differential gene expression when comparing A vs. B and A vs. C. One hundred transcripts differentially expressed in group A vs. B have been shown to be regulated by P, suggesting compromised P signaling in the endometrium. The P receptor (PR) mutation PROGINS was not detected in women from group A. Semi-quantitation of immunoreactive PRA/B, PRB and Sp1 (a transcription factor related to P signaling) in paraffin-embedded endometrial sections, did not show statistically significant differences amongst groups. However immunostaining glycodelin was significantly decreased in endometrial samples from group A

Conclusions

We conclude that some cases of repeated implantation failure could be associated with an aberrant gene expression profile. Compromised P signaling might be the underlying mechanism for such endometrial gene expression deregulation in women with repeated implantation failure.

Keywords: Endometrium, Gene expression, PROGINS, Implantation failure

Background

Cellular and molecular events in the uterine milieu that lead to successful blastocyst implantation are required in the endometrium to become receptive and ready for implantation. Acquisition of receptivity is driven by estradiol (E2) and progesterone (P), which acting through their receptors, change the transcription rate of target genes [1]. Particularly, the postovulatory rise in P triggers a sequence of highly coordinated responses beginning with the detention of the estrogen-induced epithelial cell proliferation and followed by the transformation to a secretory phenotype of the gland, recruitment of leukocytes and angiogenesis [2]. The P action is mediated primarily through binding to and activation of its cognate receptors; the full length B- and N-terminally truncated A isoforms of the P receptor (PR), classically defined as ligand-activated transcription factors [3]. Upon exposure to P, the ligand-activated receptor can directly interact with specific P-response elements (PREs) in the promoter regions of target genes. It is accepted that P acts on an estrogen primed endometrium to initiate a pattern of gene expression important for achievement of receptivity and an altered PR signaling has been associated with human endometrial dysfunction [4]. The antiprogestin mifepristone binds to the PR with high affinity blocking the biological effects of P. In women, the administration of a single dose of oral mifepristone (200 mg) during the secretory phase of the cycle rapidly renders the endometrium unreceptive and modifies gene expression in the uterus within 6 h of administration [57].

The development of microarray technology has led to many large-scale gene expression profiling studies of human endometrium [810]. Although there seems to be very few consensus genes that have been identified across similar studies [11], collectively they demonstrate that a multitude of genes are associated with the endometrial transcriptome, whose regulation for the acquisition of the receptive phenotype is ultimately driven by P. The approach our group has used to identify the endometrial receptivity transcript profile in a previous report from our laboratory [12] was to analyze endometrial tissue obtained from women during a mock hormonal treatment cycle for oocyte donation as a recipient. The endometrial samples are collected during the time interval corresponding to the window of implantation [13] comparing gene expression profiles from women who were refractory to implantation and those who achieved pregnancy in previous oocyte donation cycles [12]. Although this previous study provided interesting insights to endometrial gene expression associated with implantation failure, the microarrays analysis was performed with only 3(from a total of 5) samples from women with repeated embryo implantation failure that were pooled and using a microarrays platform that examined only one-third of the human genome; providing only a partial view of the whole picture.

The aim of the present report was to examine the individual gene expression profiles in the endometrium from women with implantation failure and compare them with those obtained from fertile women in order to identify compromised transcripts and pathways in the infertile group. We used a microarrays platform for complete coverage of the human genome and bioinformatics tools for data interpretation. Here we report that several transcripts, whose expression level is aberrant in the infertile group, have been described as regulated by P and are related to immune function.

Methods

Subjects

This study was approved by the Ethics Review Committee for Investigations in Human Beings of Faculty of Medicine, University of Chile: protocol No. 093–2008, approved 12-29-2008, initiated 01-05-2009 finished 03-31-2014. Each volunteer participating read and signed the informed consent approved by the respective Ethics Review Committee.

Three groups of women were recruited as has been described elsewhere [12]. Group A (n = 5) consisted of women that had never been pregnant and had previously participated in two or more cycles as recipients in an oocyte donation program with no evidence of embryo implantation. Male partners had normal seminal parameters and transferred embryos had good morphology, at least equivalent to embryos transferred to the oocyte donor who became pregnant. Since good quality embryos with the ability to implant and develop normally derive from good quality oocytes, it was required that the oocyte donor had become pregnant from the same oocyte pool. Women from group A were recruited within 3 years following the last failed cycle. Group B (n = 6) comprised of women who became pregnant as recipients in previous oocyte donation cycles and delivered live infants. Group C (n = 6) included normal fertile women who conceived in natural cycles and had three or more live births and had elective tubal ligation at least 1 year prior to their participation for reasons unrelated to this study. Women from groups B and C were recruited within 5 years following the last successful pregnancy. The general exclusion criteria for all volunteers included: metabolic or endocrine diseases other than those leading to ovarian failure, chronic use of medication other than HRT, polycystic ovary syndrome, drug abuse, obesity, endometriosis, pelvic inflammatory disease and current genital tract infection. Age and body mass index from recruited women as well as the plasma P and endometrial thickness measured on the day of the endometrial collection are shown in Table  1.

Table 1.

Characteristics of women participating in the study and parameters evaluated during the hormonal replacement cycle

Group A (n = 5) Group B (n = 6) Group C (n = 6) P value
Age (years) 35.4 (26–43) 41.9 (34–46) 41.3 (36–47) 0.1117
Body mass index 25.2 (22.6-29.4) 25.6 (22.5-27.4) 25.4 (23.3-28.1) 0.573
Plasma progesterone* (nmol/L) 75.7 (38–122) 88.1 (36–192) 63.7 (43.3-75) 0.7601
Endometrial thickness* (mm) 10.8 (9–12) 9.1 (8–10) 11.2 (8.5-12.5) 0.6162

*On the day of endometrial collection.

Induction of endometrial cycle

All subjects underwent the induction of an artificial endometrial cycle with exogenous ethinyl E2 for 20 days and for the last 7 days, this treatment was administered concomitantly with micronized P as described previously [12]. An endometrial sample was obtained on 20th day of the endometrial cycle. One part of the specimen was snap frozen in liquid nitrogen and kept at -80 ° C until use and the remaining portion was fixed in paraformaldehyde for histological dating, according to the criteria of Noyes et al., [14] and for immunohistochemistry (IHC) studies. All biopsies were classified as normal secretory endometrium with no signs of inflammatory processes.

Gene expression profiling

Total RNA was extracted from frozen endometrial tissue samples using Trizol (Invitrogen, Gaithersburg, MD, USA) as directed by the manufacturer and then checked for yield and quality as described before [12]. The Human Genome U133 plus 2.0 GeneChip oligonucleotide microarrays (Affymetrix, Sunnyvale, CA, USA); corresponding to 47,000 transcripts and variants, including 38,500 well-characterized human genes, was used for gene expression analysis according to the manufacturer’s instruction.

Microarrays Data Analysis: Replicate hybridizations were performed for each RNA sample and raw data obtained from the GeneChip Microarray Suite v 1.4 was subsequently analyzed using the National Cancer Institute’s Microarrays Data Base webtool (mAdb) (http://nciarray.nci.nih.gov).

Statistical analyses of microarrays data

Significant genes were defined as ≥2, p-value < 0.001 and a false discovery rate (FDR) < 0.1 [15]. T-test was performed to determine statistical differences and from the significant genes identified, Venn diagrams were constructed to identify coincident transcripts.

Hierarchical clustering

Was performed based on uncentered correlations with average linkage clustering using mAdb. The resulting dendogram allows data structure visualization of endometrial samples according to total gene expression, revealing samples with similar patterns of gene expression and relationships between the specimens.

Principal component analysis (PCA)

Was performed for simplifying the large amount of data derived from microarray analysis [16]. We applied the unbiased PCA algorithm to all samples using all transcripts analyzed with the microarray chip to look for expression patterns and underlying cluster structures of endometrial samples.

Functional clustering

To increase the effectiveness of DNA microarray analysis, data sets of differentially expressed genes from the comparison between A vs. B and A vs. C were intersected to define those transcripts consistently up- or down-regulated and combined with external data sources, such as gene annotation, in order to associate the expression patterns of this particular set of genes with the biological processes that they may represent. In our analysis, we submitted our gene lists to the web-based tools DAVID (Database for Annotation, Visualization and Integrated Discovery) [17] and GATHER (Gene Annotation Tool to Help Explain Relationships) [18] for functional annotation analysis in order to gain an in-depth understanding of their biological themes, which otherwise would require laborious and somewhat subjective manual literature searches.

DAVID

Up- and down-regulated genes were submitted to DAVID database for systematically extracting biological meaning for them by retrieving pathway maps from the Kyoto Encyclopedia of Genes and Genomes (KEGG) [19] and Biocarta pathways database (http://www.biocarta.com/genes/index.asp) along with Gene Ontology (GO) functional annotations from Entrez Gene [20]. The parameters of the “Functional Annotation Clustering” (a part of the “Functional Annotation Tool”) were set to the highest level of stringency in order to obtain the smallest number of maps. The DAVID database associates each annotation to a gene group using a contingency table representation and calculates its significance.

GATHER

Regulated genes were submitted as well to GATHER database (http://gather.genome.duke.edu/) that contains the GO annotations and KEGG pathways. The GATHER database associates each group of transcripts with the same functional annotation and calculates a Bayes factor [18] which is a measure of the strength of the evidence supporting an association of an annotation with the submitted gene list. We have selected a low Bayes factor (≥3) for presenting the preponderant evidences for associations.

Immunohistochemistry (IHC)

A portion of each endometrial sample was fixed in paraformaldehyde, included in paraffin blocks and 5 μm sections were prepared. PR-A/B, PR-B, glycodelin and Specificity protein 1 (Sp1) were evaluated by IHC in the endometrial samples using the antibodies and dilutions shown in Table  2 and the broad spectrum Histostain-SP kit (Life Technologies, Carlsbad, CA, USA) as described previously [21]. Immunoreactive PRA/B, PRB, Sp1 and glycodelin in endometrial sections was semi-quantified using the expression level score (ELS), calculated by means of Image Pro Plus software (Media Cybernetics Rockville, MD, USA) as described previously [21]. Briefly, ELS = Mean Optical Density of immunostaining x Percent Area Positively Stained x 100.

Table 2.

Antibodies and dilutions used for immunohistochemistry

Antibody Source Dilution
Progesterone receptor (PR)-A/B Santa Cruz Biotech. (sc-810) 1:50
PR-B Novocastra (NCL-PGR-B) 1:100
Glycodelin H. Koistinen [22] 1:1000
Specificity protein-1 (Sp1) Santa Cruz Biotech. (sc-14027) 1:100

DNA isolation and PROGINSdetection

Genomic DNA was isolated from leukocytes derived from peripheral blood obtained by venipuncture using the PAXgene Blood DNA Validation kit (Qiagen, Valencia, CA, USA) following the manufacturer’s protocol. The detection of Alu insertion in intron G and restriction fragment length polymorphism (RFLP) analysis in exon 5 to confirm the presence of PROGINS mutation was performed as described by Pisarska et al. [23].

Results

Gene expression profile analysis

Women with implantation failure (group A, n = 5), women with 2 or more livebirths conceived either by oocyte donation (group B, n = 6) or naturally (group C, n = 6) were subjected to an oocyte donation mock cycle as recipients and on the seventh day of P administration an endometrial sample was obtained. Total RNA was extracted from each tissue sample and used to individually probe the HG_U133 plus 2.0 human gene microarray comprising of 54,675 genes and expressed sequence tags.We performed PCA for all the endometrial samples analyzed using their respective gene expression profiles for their representation on a three-dimensional graphic (Figure  1A). Each point in a PCA graph represents the gene expression profile of an endometrial sample and the distance between two plotted points is proportional to the degree of similarity between the gene expression profiles. The PCA plot comprising of a projection on the first three principal components, which together explain 48.8% (21%, 14%, and 13%) of the total variance, showed that endometrial samples from infertile subjects clustered apart from samples belonging to the control groups. In addition, gene expression profiles from endometrial samples obtained from microarray analysis were subjected to unsupervised hierarchical clustering analysis in order to generate a dendogram, which is a tree-structured graph that illustrates the similarities in gene expression profiles between endometrial samples from all groups. The dendogram obtained displayed a striking segregation of samples into two major clustering branches, corresponding to the implantation failure group (Group A) and the successful implantation groups (Groups B and C, Figure  1B).

Figure 1.

Figure 1

Principal component analysis (PCA) plot of gene expression profiles from endometrial samples and Venn diagrams from differentially expressed transcripts. A, The profiles from infertile women (group A (n = 5); red dots) cluster separately to clusters representative of women with embryo implantation (groups B (n = 6) and C (n = 6); green and blue dots, respectively). B, hierarchical clustering analysis represented in a tree-like dendogram revealing the similarities on gene expression profiles of endometrial samples. A clear segregation of samples into two major clustering branches, one with samples from group A and the other with samples form groups B and C that self-cluster together. C, Venn diagrams showing the differentially expressed genes in each group, which are either 2-fold down- (panel C) or up-regulated (panel D) in endometrial samples from women with implantation failure (group A) compared to those from women that conceived either by IVF (Group B) or naturally (group C).

The microarrays data analysis revealed that 747 transcripts were down-regulated in group A compared to group B; whereas 218 transcripts were up-regulated (Figure  1C and 1D). When group A was compared to group C, 156 and 884 transcripts were decreased and increased respectively in group A (Figure  1C and 1D). Only 31 and 51 transcripts down- and up-regulated respectively were common when comparing group A with the control groups B and C (Figure  1C and 1D). The lists of common differentially expressed genes in the comparison of gene expression profiles from group A vs. Group B and Group A vs. group C is in Table  3 for down- and Table  4 for up-regulated transcripts. An independent validation by Real Time RT-PCR for some of the differentially expressed genes found in the samples used in this study has been reported elsewhere [12], supporting our microarrays findings.

Table 3.

Genes whose transcript level was down-regulated in Group A (n = 5) when compared with Group B (n = 6) and Group C (n = 6) in the microarray analyses

UniGene ID Gene symbol Gene title A vs. B p value A vs. C p value Average
Hs.699841 IGHA1 Immunoglobulin heavy constant alpha 1 0.1 0.00086 0.08 0.00043 0.09
Hs.436657 CLU Clusterin 0.11 0.00043 0.17 0.00013 0.14
Hs.356624 NID1 Nidogen 1 0.19 0.00013 0.14 0.00022 0.16
Hs.82071 CITED2 Cbp/p300-interacting transactivator. with Glu/Asp-rich carboxy-terminal domain. 2 0.15 0.00086 0.19 0.00043 0.17
Hs.532325 PAEP Progestagen-associated endometrial protein (PAEP) 0.09 0.00086 0.29 0.00086 0.19
Hs.38972 TSPAN1 Tetraspanin 1 0.14 0.00022 0.24 0.00086 0.19
Hs.445705 RRM1 Ribonucleotide reductase M1 0.18 0.00043 0.23 0.00022 0.2
Hs.1012 C4BPA Complement component 4 binding protein. alpha 0.21 0.00043 0.22 0.00043 0.22
Hs.513261 HN1L Hematological and neurological expressed 1-like 0.18 0.00022 0.35 0.00043 0.26
Hs.80658 UCP2 Uncoupling protein 2 (mitochondrial. proton carrier) 0.1 0.00043 0.49 0.00013 0.29
Hs.502989 UNC93B1 Unc-93 homolog B1 (C. elegans) 0.23 0.00013 0.37 0.00043 0.3
Hs.414099 CNPY3 Canopy 3 homolog (zebrafish) 0.29 0.00013 0.32 0.00022 0.31
Hs.110571 GADD45B Growth arrest and DNA-damage-inducible. beta 0.2 0.00022 0.44 0.00086 0.32
Hs.320151 AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase. beta) 0.23 0.00086 0.43 0.00013 0.33
Hs.77422 PLP2 Proteolipid protein 2 (colonic epithelium-enriched) 0.26 0.00043 0.42 0.00043 0.34
Hs.1497 RARG Retinoic acid receptor. gamma 0.33 0.00043 0.35 0.00043 0.34
Hs.389700 MGST1 Glutathione S-transferase. microsomal 0.4 0.00022 0.29 0.00043 0.34
Hs.292078 LARP1 La ribonucleoprotein domain family. member 1 0.34 0.00043 0.36 0.00086 0.35
Hs.334587 RBPMS RNA binding protein with multiple splicing 0.29 0.00086 0.43 0.00022 0.36
Hs.5298 ADIPOR1 Adiponectin receptor 1 0.3 0.00022 0.42 0.00013 0.36
Hs.439894 CASZ1 Castor zinc finger 1 0.24 0.00022 0.49 0.00086 0.37
Hs.371727 SCNN1G Sodium channel. nonvoltage-gated 1. gamma 0.29 0.00013 0.45 0.00043 0.37
Hs.474596 LIMK2 LIM domain kinase 2 0.26 0.00043 0.5 0.00013 0.38
Hs.459940 LITAF Lipopolysaccharide-induced TNF factor 0.37 0.00022 0.39 0.00086 0.38
Hs.442449 CHST14 Carbohydrate (N-acetylgalactosamine 4–0) sulfotransferase 14 0.42 0.00086 0.35 0.00086 0.38
Hs.518525 GLUL Glutamate-ammonia ligase 0.42 0.00043 0.48 0.00086 0.45
Hs.119177 ARF3 ADP-ribosylation factor 3 0.47 0.00013 0.45 0.00043 0.46
Hs.497417 KIAA0317 KIAA0317 0.49 0.00086 0.44 0.00013 0.46
Hs.501728 RHOG Ras homolog gene family. member G (rho G) 0.46 0.00043 0.47 0.00043 0.47
Hs.414614 SCNN1B Sodium channel. nonvoltage-gated 1. beta 0.48 0.00013 0.47 0.00022 0.47
Hs.436896 POLR3A Polymerase (RNA) III (DNA directed) polypeptide A. 155 kDa 0.48 0.00043 0.47 0.00043 0.48

Data includes genes with decreased transcript levels displaying a ≥2-fold difference in average A vs. B and A vs. C.

Table 4.

Genes whose transcript level was up-regulated in Group A (n = 5) when compared with Group B (n = 6) and Group C (n = 6) in the microarray analyses

UniGene ID Gene symbol Gene title A vs. B p value A vs. C p value Average
Hs.35086 USP1 Ubiquitin specific protease 1 (USP1), mRNA. 42.52 0.00022 44.32 0.00043 43.42
Hs.436977 SYTL3 Synaptotagmin-like 3 20.68 0.00043 26.72 0.00013 23.70
Hs.133421 LIFR Leukemia inhibitory factor receptor 43.71 0.00086 3.32 0.00022 23.52
Hs.160211 THRAP3 Thyroid hormone receptor associated protein 3 (THRAP3), mRNA. 29.04 0.00013 3.66 0.00043 16.35
Hs.532399 ZC3H11A KIAA0663 gene product (KIAA0663), mRNA. 4.38 0.00043 28.05 0.00086 16.21
Hs.652169 PLGLB2 Plasminogen-like B2 21.71 0.00086 9.45 0.00086 15.58
Hs.524809 CLIP1 Restin (Reed-Steinberg cell-expressed intermediate filament-associated protein) (RSN), transcript variant 2, mRNA. 2.19 0.00043 25.81 0.00043 14.00
Hs.16355 MYH10 Myosin, heavy polypeptide 10, non-muscle (MYH10), mRNA. 2.6 0.00013 24.08 0.00022 13.34
Hs.502829 SF1 Splicing factor 1 (SF1), transcript variant 4, mRNA. 21.86 0.00043 4.08 0.00086 12.97
Hs.517949 MAP4 Microtubule-associated protein 4 (MAP4), transcript variant 1, mRNA. 10.41 0.00043 11.96 0.00013 11.18
Hs.8118 SMCHD1 KIAA0650 protein 18.77 0.00013 2.17 0.00043 10.47
Hs.514806 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) (GALNT1), mRNA. 11 0.00043 9.38 0.00043 10.19
Hs.130293 LUC7L3 Cisplatin resistance-associated overexpressed protein (CROP), transcript variant 2, mRNA. 6.32 0.00043 11.88 0.00022 9.10
Hs.143728 WASL Wiskott-Aldrich syndrome-like (WASL), mRNA. 2.07 0.00022 14.32 0.00086 8.20
Hs.532082 IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) (IL6ST), transcript variant 2, mRNA. 2.95 0.00013 13 0.00043 7.97
Hs.2913 EPHB3 EphB3 = HEK2 = tyrosine kinase receptor = large erk kinase 11.39 0.00086 4.41 0.00086 7.90
Hs.431081 USP53 Ubiquitin specific protease 53 2.23 0.00013 13.55 0.00043 7.89
Hs.194726 BAG4 BCL2-associated athanogene 4 (BAG4), mRNA. 11.71 0.00013 3.16 0.00086 7.44
Hs.464971 PIK3C3 Phosphoinositide-3-kinase, class 3 3.92 0.00043 10.41 0.00086 7.16
Hs.9997 SECISBP2L KIAA0256 gene product (KIAA0256), mRNA. 5.43 0.00086 7.36 0.00013 6.39
Hs.497788 EPRS Glutamyl-prolyl-tRNA synthetase (EPRS), mRNA. 4.41 0.00043 8.11 0.00043 6.26
Hs.101014 CEP57 Translokin (KIAA0092), mRNA. 5.03 0.00086 7.31 0.00086 6.17
Hs.143600 GOLIM4 Golgi phosphoprotein 4 (GOLPH4), mRNA. 2.46 0.00043 9.85 0.00022 6.16
Hs.24485 SMC3 Chondroitin sulfate proteoglycan 6 (bamacan) (CSPG6), mRNA. 2.53 0.00022 9.65 0.00043 6.09
Hs.193832 GPATCH4 G patch domain containing 4 (GPATC4), transcript variant 3, mRNA. 3.32 0.00013 7.94 0.00086 5.63
Hs.406695 PRDM7 PR domain containing 7 (PRDM7), mRNA. 2.04 0.00086 8.46 0.00086 5.25
Hs.42194 SPCS3 Signal peptidase complex subunit 3 homolog (S. cerevisiae) (SPCS3), mRNA. 2.1 0.00043 8.34 0.00022 5.22
Hs.458418 KIAA1731 PREDICTED: KIAA1731 protein (KIAA1731), mRNA. 2.04 0.00013 8.4 0.00086 5.22
Hs.49853 CCAR1 Cell division cycle and apoptosis regulator 1 2.75 0.00086 7.67 0.00013 5.21
Hs.496414 ATP7A ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) 2.89 0.00086 7.16 0.00043 5.02
Hs.481181 NEK1 NIMA (never in mitosis gene a)-related kinase 1 (NEK1), mRNA. 3.07 0.00086 5.35 0.00043 4.21
Hs.440833 PKN2 protein kinase N2 (PKN2), mRNA. 6.02 0.00022 2.14 0.00043 4.08
Hs.524009 AASDHPPT Aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 3.89 0.00013 4.2 0.00086 4.04
Hs.26904 SEC63 SEC63 homolog (S. cerevisiae) 2.95 0.00086 3.78 0.00043 3.37
Hs.93485 SCN2A MRNA; cDNA DKFZp761D191 (from clone DKFZp761D191) 2.08 0.00043 4.5 0.00013 3.29
Hs.31082 TMEM33 Transmembrane protein 33 2.19 0.00086 4.35 0.00043 3.27
Hs.371372 CWC27 Serologically defined colon cancer antigen 10 (SDCCAG10), mRNA. 2.95 0.00043 3.51 0.00086 3.23
Hs.523299 EIF3A Eukaryotic translation initiation factor 3, subunit 10 theta, 150/170 kDa (EIF3S10), mRNA. 2.68 0.00022 3.58 0.00022 3.13
Hs.440320 CUL5 Cullin 5 (CUL5), mRNA. 2.6 0.00043 3.25 0.00043 2.93
Hs.203965 PHTF2 Putative homeodomain transcription factor 2 3.56 0.00013 2.3 0.00086 2.93
Hs.335068 TGS1 Nuclear receptor coactivator 6 interacting protein (NCOA6IP), mRNA. 3.63 0.00086 2.16 0.00013 2.89
Hs.189075 TWF1 Twinfilin, actin-binding protein, homolog 1 (Drosophila) 2.36 0.00086 2.97 0.00043 2.67
Hs.127310 UHMK1 U2AF homology motif (UHM) kinase 1 (UHMK1), mRNA. 2.85 0.00086 2.46 0.00043 2.66
Hs.430849 OSBPL8 Oxysterol binding protein-like 8 (OSBPL8), transcript variant 1, mRNA. 2.03 0.00022 3.05 0.00022 2.54
Hs.150557 KLF9 Basic transcription element binding protein 1 (BTEB1), mRNA. 2.6 0.00086 2.39 0.00043 2.50
Hs.210850 HECTD1 HECT domain containing 1 (HECTD1), mRNA. 2.35 0.00013 2.6 0.00086 2.47
Hs.142442 HP1BP3 Heterochromatin protein 1, binding protein 3 2.08 0.00086 2.41 0.00013 2.25
Hs.369284 ESF1 Chromosome 20 open reading frame 6 (C20orf6), mRNA. 2.13 0.00013 2.3 0.00086 2.21
Hs.119023 SMC2 SMC2 structural maintenance of chromosomes 2-like 1 (yeast) (SMC2L1), mRNA. 2.25 0.00022 2 0.00022 2.13
Hs.481927 NIPBL Nipped-B homolog (Drosophila) 2.11 0.00043 2.04 0.00086 2.08
Hs.374201 KIF21A kinesin family member 21A (KIF21A), mRNA. 2.13 0.00013 2 0.00013 2.06

Data includes genes with increased transcript levels displaying a ≥2-fold difference in average A vs. B and A vs. C.

Functional associations of transcripts dysregulated in group A vs. control groups

In order to gain further understanding of the potential functional roles of dysregulated endometrial transcripts from group A, we obtained the functional annotations from each gene and determined the enriched processes associated to them from two different web-based tools. Within the down-regulated transcripts, the functional classifications immune response and complement activation, classical pathway were found to be statistically over-represented using the web based applications DAVID and GATHER respectively (p < 0.01). The Bayes factor obtained with the analysis using the GATHER database was 3, which indicates that the association of this particular function with the total of the transcripts in our gene list is weak. The up-regulated transcript list was not enriched with transcripts related to a particular function.

P-regulated genes in women with implantation failure (group A) vs. control (group B)

We reasoned that the endometrium of women from group A might have a dysregulation in P-regulated transcripts as it has been described for endometriosis and also these genes might be coincident with those whose expression in the endometrium is altered upon treatment with the PR antagonist mifepristone. Since women from groups A and B only differ on the embryo implantation outcome, the list of dysregulated transcripts in group A vs. group B during the receptive phase of the endometrium was selected. Within this repertoire, we searched for those genes known to be regulated in normal cycling endometrium by P as it has been described before [4]. For that we accounted for those transcripts that, directed by P, get regulated for the acquisition of endometrial receptivity [2432] and/or dysregulated in conditions that render the endometrium with an unreceptive phenotype (i.e., endometriosis and mifepristone treatment) and that intersected with our list of up and down regulated genes (i.e., A vs. B). We considered only those that had the opposite regulation compared with receptive endometrium, and same regulation in endometrium from women with compromised P signaling in the endometrium such as treated with mifepristone [7] and/or from women with endometriosis [4]. We found 14 and 86 up- and down-regulated genes respectively in the endometrium during the receptive period of women with implantation failure vs. control group B (Tables  5 and 6).

Table 5.

Genes previously described to be progesterone regulated that are down-regulated in endometrium of subjects with repeated embryo implantation failure

UniGene ID Gene symbol Gene title Up regulated in window of implantation Down regulated in endometriosis or mifepristone Fold change p value
Hs.386793 GPX3 Glutathione peroxidase 3 (plasma) (GPX3), mRNA. [25, 27, 29, 32] 0.01 0.00013
Hs.458355 C1S Complement component 1, s subcomponent, transcript variant 1, mRNA. [28, 29] 0.02 0.00043
Hs.647023 CLDN3 Claudin 3 [24] 0.07 0.00086
Hs.89603 MUC1 Mucin 1, transmembrane, mRNA. [25] [4] 0.11 0.00022
Hs.436657 CLU Clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J), transcript variant 1, mRNA. [27, 29, 31, 32] 0.12 0.00086
Hs.276770 CD52 CD52 molecule [7] 0.14 0.00043
Hs.498173 SMPD1 Sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase), transcript variant 1, mRNA. [24, 26] 0.14 0.00013
Hs.523414 LOC492304 Putative insulin-like growth factor II associated protein, mRNA. [27] 0.15 0.00022
Hs.532325 PAEP Progestagen-associated endometrial protein [24, 25, 27, 31, 32] [39] 0.15 0.00086
Hs.590970 AXL AXL receptor tyrosine kinase [24] 0.15 0.00022
Hs.163893 PICALM Phosphatidylinositol binding clathrin assembly protein [4] 0.16 0.00086
Hs.525607 TNFAIP2 Tumor necrosis factor, alpha-induced protein 2, mRNA. [2729, 32] 0.18 0.00043
Hs.654439 APOE Apolipoprotein E [24, 29] 0.18 0.00086
Hs.201978 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase), transcript variant 2, mRNA. [29] [7] 0.19 0.00013
Hs.82071 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2, mRNA. [25] 0.19 0.00086
Hs.524518 STAT6 Signal transducer and activator of transcription 6, interleukin-4 induced, mRNA. [29] 0.19 0.00022
Hs.478588 BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51), transcript variant 1, mRNA. [25, 27, 29] 0.20 0.00086
Hs.1012 C4BPA Complement component 4 binding protein, alpha [24, 25, 27, 29, 31, 32] [39] 0.22 0.00043
Hs.21765 FADS3 Fatty acid desaturase 3, mRNA. [26] 0.23 0.00043
Hs.4055 KLF6 Kruppel-like factor 6 [25] 0.23 0.00013
Hs.332708 FBLN5 Fibulin 5, mRNA. [27, 29] 0.23 0.00022
Hs.25292 JUNB Jun B proto-oncogene, mRNA. [25, 26] 0.25 0.00043
Hs.431048 ABL1 V-abl Abelson murine leukemia viral oncogene homolog 1, transcript variant b, mRNA. [24] 0.27 0.00086
Hs.190783 HAL Histidine ammonia-lyase [26, 32] 0.27 0.00086
Hs.513984 FLII Flightless I homolog (Drosophila), mRNA. [24, 32] 0.27 0.00043
Hs.643357 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 [29] 0.29 0.00022
Hs.44227 HPSE Heparanase [29] 0.29 0.00086
Hs.515536 RRAS Related RAS viral (r-ras) oncogene homolog, mRNA. [27] 0.29 0.00013
Hs.409578 STK38 Serine/threonine kinase 38 [26] 0.29 0.00043
Hs.549171 C1orf56 Chromosome 1 open reading frame 56 [7] 0.29 0.00022
Hs.494457 NINJ1 Ninjurin 1, mRNA. [26] 0.29 0.00013
Hs.270291 ACTN4 Actinin, alpha 4 (ACTN4), mRNA. [29] 0.29 0.00086
Hs.381099 LCP1 Lymphocyte cytosolic protein 1 (L-plastin), mRNA. [28, 29] 0.31 0.00043
Hs.185172 GNB2 Guanine nucleotide binding protein (G protein), beta polypeptide 2, mRNA. [26] 0.31 0.00013
Hs.1497 RARG Retinoic acid receptor, gamma [7] 0.33 0.00043
Hs.474751 MYH9 Myosin, heavy polypeptide 9, non-muscle, mRNA. [29] 0.33 0.00043
Hs.255093 PFKL Phosphofructokinase, liver, transcript variant 2, mRNA. [24] 0.33 0.00086
Hs.503911 NNMT Nicotinamide N-methyltransferase [25, 27] 0.33 0.00043
Hs.504877 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta , mRNA. [24, 26, 27, 29] 0.33 0.00022
Hs.210995 CA12 Carbonic anhydrase XII, transcript variant 2, mRNA. [27, 32] 0.35 0.00043
Hs.520640 ACTB Actin, beta, mRNA. [7] 0.35 0.00086
Hs.514819 AP2B1 Adaptor-related protein complex 2, beta 1 subunit, mRNA. [24] 0.35 0.00013
Hs.511605 ANXA2 Annexin A2, transcript variant 2, mRNA. [29] 0.35 0.00086
Hs.87752 MSN Moesin, mRNA. [29] 0.35 0.00022
Hs.654958 ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 [7] 0.35 0.00013
Hs.443577 TNFRSF21 Tumor necrosis factor receptor superfamily, member 21 [29] [4] 0.35 0.00086
Hs.591868 ZBTB10 Zinc finger and BTB domain containing 10 [4] 0.35 0.00043
Hs.25348 VAMP2 Vesicle-associated membrane protein 2 (synaptobrevin 2) [4] 0.38 0.00086
Hs.159161 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha, mRNA. [24] [7] 0.38 0.00022
Hs.131269 RARRES1 Retinoic acid receptor responder (tazarotene induced) 1 [27] 0.38 0.00086
Hs.513915 CLDN7 Claudin 7, mRNA. [25] 0.38 0.00013
Hs.10326 COPE Coatomer protein complex, subunit epsilon, transcript variant 2, mRNA. [24] 0.38 0.00013
Hs.416024 NRSN2 Neurensin 2 [7] 0.38 0.00043
Hs.434248 PLEC Plectin [26, 29] [39] 0.38 0.00086
Hs.584854 AVIL Advillin [26, 29] 0.41 0.00022
Hs.183109 MAOA Monoamine oxidase A [24, 25, 27, 28, 31, 32] 0.41 0.00013
Hs.365405 SELO Selenoprotein O [4] 0.41 0.00013
Hs.645228 KIR3DL1 Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 [29] 0.41 0.00086
Hs.528299 HTATIP HIV-1 Tat interacting protein, 60 kDa, transcript variant 3, mRNA. [26] 0.41 0.00043
Hs.164226 THBS1 Thrombospondin 1, mRNA. [29] 0.41 0.00086
Hs.647078 CDK5 Cyclin-dependent kinase 5 [7] 0.41 0.00043
Hs.278573 CD59 CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344), transcript variant 2, mRNA. [29] 0.41 0.00022
Hs.515162 CALR Calreticulin [7] 0.41 0.00043
Hs.465744 INSR Insulin receptor [26] 0.41 0.00013
Hs.274256 ELOVL7 ELOVL family member 7, elongation of long chain fatty acids (yeast) [4] 0.44 0.00086
Hs.450230 IGFBP3 Insulin-like growth factor binding protein 3 [27, 29, 32] 0.44 0.00086
Hs.504687 MYL9 Myosin, light polypeptide 9, regulatory [27] 0.44 0.00022
Hs.446641 ARAF V-raf murine sarcoma 3611 viral oncogene homolog, mRNA. [25] 0.44 0.00086
Hs.2030 THBD Thrombomodulin [25, 27, 29] 0.44 0.00013
Hs.104672 FILIP1L Filamin A interacting protein 1-like [27] 0.44 0.00086
Hs.75862 SMAD4 SMAD family member 4 [4] 0.44 0.00022
Hs.520757 TBXAS1 Thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A), transcript variant TXS-II, mRNA. [29] 0.47 0.00013
Hs.283741 EXOSC5 Exosome component 5 [7] 0.47 0.00086
Hs.174312 TLR4 Toll-like receptor 4, transcript variant 2, mRNA. [29] 0.47 0.00043
Hs.24601 FBLN1 Fibulin 1 [31] [7] 0.47 0.00086
Hs.501728 RHOG Ras homolog gene family, member G (rho G) [7] 0.47 0.00043
Hs.220864 CHD2 Chromodomain helicase DNA binding protein 2 [4] 0.47 0.00086
Hs.524809 CLIP1 CAP-GLY domain containing linker protein 1 [29] 0.47 0.00043
Hs.92236 MLL4 Myeloid/lymphoid or mixed-lineage leukemia 4 [7] 0.47 0.00086
Hs.654688 MKL1 Megakaryoblastic leukemia (translocation) 1 [26] 0.47 0.00043
Hs.279837 GSTM2 Glutathione S-transferase mu 2 (muscle) [26] 0.47 0.00086
Hs.645227 TGFB1 Transforming growth factor, beta 1 [7] 0.50 0.00086
Hs.149261 RUNX1 Runt-related transcription factor 1 [27] 0.50 0.00013
Hs.522818 L1CAM L1 cell adhesion molecule (hydrocephalus, stenosis of aqueduct of Sylvius 1, MASA (mental retardation, aphasia, shuffling gait and adducted thumbs) syndrome, spastic paraplegia 1) [26] 0.50 0.00043
Hs.840 IDO1 Indoleamine 2,3-dioxygenase 1 [24, 25, 29] 0.50 0.00086
Hs.2256 MMP7 Matrix metalloproteinase 7 (matrilysin, uterine) [27] 0.50 0.00043

Data is expressed as fold change for endometrial genes down-regulated ≥2-fold in group A vs. group B that have been shown either up-regulated during the window of implantation or down-regulated in women with endometriosis or treated with mifepristone. Bolded transcripts are decreased also in group A vs. Group C.

Table 6.

Genes previously described to be progesterone regulated that are up-regulated in endometrium of subjects with repeated embryo implantation failure

UniGene ID Gene symbol Gene title Down regulated in window of implantation Up regulated in endometriosis or RU486 Fold change p value
Hs.208854 CD69 CD69 antigen (p60, early T-cell activation antigen) [7] 2,3 0.00022
Hs.406515 NQO1 NAD(P)H dehydrogenase, quinone 1 [29] 2,2 0.00043
Hs.335614 SEC14L2 SEC14-like 2 (S. cerevisiae), mRNA. [4] 1,9 0.00013
Hs.481181 NEK1 NIMA (never in mitosis gene a)-related kinase 1 (NEK1), mRNA. [29] 1,6 0.00043
Hs.86368 CLGN Calmegin, mRNA. [7] 1,5 0.00086
Hs.189075 TWF1 Twinfilin, actin-binding protein, homolog 1 (Drosophila) [4] 1,5 0.00043
Hs.127680 LOC389332 PREDICTED: hypothetical LOC389332 (LOC389332), mRNA. [4] 1,4 0.00013
Hs.369430 PAM Peptidylglycine alpha-amidating monooxygenase, transcript variant 3, mRNA. [24, 28] 1,1 0.00022
Hs.514806 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1), mRNA. [7] 1,1 0.00043
Hs.509447 GRLF1 Glucocorticoid receptor DNA binding factor 1 [7] 1,1 0.00086
Hs.481927 NIPBL Nipped-B homolog (Drosophila) [7] 1,1 0.00086
Hs.444558 KHDRBS3 KH domain containing, RNA binding, signal transduction associated 3, mRNA. [24, 29, 32] [4] 1,1 0.00043
Hs.495710 GPM6B Glycoprotein M6B (GPM6B), transcript variant 4, mRNA. [29] 1,0 0.00022
Hs.496414 ATP7A ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome) [29] 1,0 0.00043

Data is expressed as fold change for endometrial genes up-regulated ≥2-fold in group A vs. group B that have been shown either down-regulated during the window of implantation or up-regulated in women with endometriosis or treated with mifepristone. Bolded transcripts are increased also in group A vs. Group C.

PROGINS detection

Since the comparative gene expression analysis of P-regulated genes in endometrial samples from group A, suggested an altered P response, we determined the presence of the Alu insertion in intron G of the PR gene (PROGINS) in women from groups A, B and C. Restriction fragment length polymorphism (RFLP) analysis was also carried out on exon 5 of PR gene for confirmation. We found 4 heterozygous subjects for pgr (Figures  2A and B). Two were from group B and two from group C, whereas no PROGINS alleles were detected in women from group A.

Figure 2.

Figure 2

Screening for PROGINS allele. A, identification of Alu insertion in Intron G. The Alu insertion in the progesterone receptor gene generates a 494-bp PCR product compared to the 174-bp fragment obtained for the wild type. Samples 04, 05, 24 and 25 with bands at 494 bp and 174 bp indicate the presence of PROGINS in the heterozygous state. All the other lanes with a single fragment of 174 bp indicate the presence of the wild-type progesterone receptor in the homozygous state. B, restriction digestion of exon 5 with NlaIII. Lanes for samples 04, 05, 24 and 25 confirm the presence of PROGINS in heterozygous state; NlaIII cleaves the PCR product into two fragments, 106 and 53 bp. All the other samples displayed the uncleaved 159-bp fragment only, indicating the presence of the wild type receptor.

IHC analysis

Since the levels of both isoforms of PR in human endometrium have been found to be abnormal in patients with endometriosis [33, 34], we evaluated the immunoreactive presence of PR-A/B (Figures  3A and 3C), PR-B (Figures  3D and 3F) along with Sp1 (Figure  3G and 3I) and the P-regulated glycoprotein glycodelin (Figures  3 J and 3L) in paraformaldehyde-fixed paraffin embedded endometrial tissue from groups A, B and C by IHC. Immunostaining was semi-quantified by calculating the respective ELS scores for each detected molecule in all groups of women (Figure  4). ELS for glycodelin in groups B and C was 10.6 and 12.1 fold from group A respectively (p = 0.00509, Figure  4A). The presence of PR-A/B and PR-B in endometrial tissue was evaluated (Figures  3A-C and 3D-F, respectively), since a possible post-translational dysregulation of PR expression (not detected by transcript analysis) might explain the differential gene expression of P-regulated genes in the endometrium from women of group A such as glycodelin. The ELS scores obtained for PR-A/B and PRB did not show significant differences amongst groups (Figures  4B and 4C respectively). In addition, semi-quantitation of immunoreactive Sp1, a known co-activator and trans-activator of the PR that mediates P-induced glycodelin expression, did not show significant differences amongst groups A, B and C (Figure  4D).

Figure 3.

Figure 3

Immunodetection of progesterone receptor (A and B isoforms, PR), progesterone receptor B (PRB), Specificity Protein 1 (Sp1) and glycodelin in endometrial sections. Representative photomicrographs of endometrial sections immunostained in triplicate for PR (panels A, B and C), PRB (panels D, E and F), Sp1 (panels G, H and I) and glycodelin (panels J, K and L) are shown in women from group A (panels A, D, G and J; n = 5), group B (panels B, E, H and K; n = 6) and group C (panels C, F, I and L; n = 6).

Figure 4.

Figure 4

Immunohistochemistry semiquantitation. Expression Level Score (ELS) for immunostaining of glycodelin (panel A), PRA/B (panel B), PRB (panel C) and Sp1 (panel D) in endometrial sections from groups A (n = 5), B (n = 6) and C (n = 6). Data is expressed as average ELS ± SD for each group. *p < 0.05, Kruskal Wallis U-test.

Discussion

Uterine receptivity is defined as a restricted time-related period when the uterus is receptive to blastocyst attachment and implantation. The establishment of this endometrial transition, which supports embryo implantation, is primarily coordinated by ovarian hormones, E2 and P that modulate uterine events in a spatiotemporal manner.

Endometrial factors, at the molecular level, have been suggested to explain some cases of infertility, recurrent miscarriages and implantation failure after IVF. In the present study we assessed the endometrial gene expression profile during the receptive period in mock oocyte donation cycles of women with repeated embryo implantation failure (Group A). Their profiles were compared with those obtained from women who achieved embryo implantation and pregnancy in oocyte donation cycles (Group B), or which got pregnant in natural spontaneous cycles (Group C). The data suggest a strong association between an aberrant endometrial gene expression and implantation failure. The stimulation protocol with steroid hormones performed before the endometrial sample collection was the same for all participating women in this study. Hence, the differential transcript profile in Group A suggests a long-term dysregulation of endometrial gene regulation rendering it not suitable for embryo implantation. The functional annotation analysis of dysregulated transcripts showed an enrichment of decreased genes involved in immune response and complement activation in women with repeated implantation failure.

Integration and cross-validation of endometrial transcripts regulated by P could increase the confidence in expression results for many more genes than is tractable with classical one-by-one validation of differentially expressed genes and should provide the up- and down-regulated genes that together orchestrate the acquisition of the receptive phenotype of the endometrium for embryo implantation. Such exploration and integration could help to get a comprehensive view of existing data needed to better prioritize experimental efforts. We identified a subset of P-regulated transcripts with differential expression in the endometrium of women from group A compared to the control group B revealing compromised P-signalling in the endometrium.

Pisarska et al. [23] reported that 42% of women with unexplained infertility carry the allele for the PROGINS mutation compared with 14% of control fertile women (with at least 1 term pregnancy). We analyzed the presence of the PROGINS allele in women from groups A, B and C and found no correlation between the PROGINS carrier women and altered transcript levels of P-regulated genes in the endometrium. This result is in line with a study from Coulam et al. [35] that did not find an association between PR polymorphisms with recurrent implantation failure in women after in vitro fertilization and embryo transfer.

Glycodelin, encoded by the gene PAEP [36, 37] is the main P-regulated glycoprotein secreted by the endometrial epithelium during the secretory phase and early pregnancy [38]. The transcript levels for PAEP have also been consistently identified to be one of the most abundant in the endometrium by several gene expression profiling studies [24, 25, 27, 31], and it has been shown to be decreased in women with endometriosis [39]. In the present study we found that the transcript levels for PAEP were decreased in the endometrium of women from group A compared to both control groups (Table  5). In addition, immunoreactive glycodelin evaluation in endometrial sections showed the protein to be significantly decreased in group A which is in line with the microarrays data. These results are consistent with the reduced concentrations of glycodelin in uterine flushing reported for patients with unexplained infertility [40]. In normal ovulatory cycles, P secretion is followed by endometrial glycodelin synthesis in epithelial glands from 4 to 5 postovulatory days onwards [37, 41]. Endometrial epithelial cells stimulated in vitro with progestins showed an increase in glycodelin transcription, synthesis, and secretion [42] however a PR-antagonist failed to prevent the induction of glycodelin [43]. In silico analysis of PAEP gene promoter sequence identified a potential P response element [44], however functional studies found that the transcription factor Sp1 mediates the effect of P and PR on human glycodelin expression in endometrial cells [45]. We semiquantified the immunoreactive levels of PR-A/B, PR-B and Sp1 in endometrial sections of women from groups A, B and C and found no significant differences between the groups.

The endometrial response to the increased circulating levels of P during the luteal phase has shown to be remarkably different in women with endometriosis compared to healthy controls. Such response has been evidenced by dysregulated specific gene networks of P-dependent genes in patients with endometriosis compared to non-diseased patients in eutopic secretory endometrium [4, 39, 46, 47]. This transcriptional behavior has led to the concept of ‘P resistance’ which may explain the association between pelvic endometriosis and infertility. We have found that the endometrial transcript profile from women with repeated implantation failure (group A) presents altered gene expression profile including several transcripts reported to be P-regulated, suggesting a women from group A have a compromised P signalling in the endometrium.

The cause of this endometrial defect is unknown, although the apparent intrinsic dysregulation in P signalling that renders the endometrium unreceptive in women with repeated embryo implantation failure seems to be beyond perturbations in PR expression such as chaperone proteins involved in receptor recycling and ligand binding [48], coregulators [4951], as well as associated transcription factors and a variety of upstream signal transduction pathways capable of modifying PR and its coregulators [5256]. In addition, the action of the P is not limited to the cell type in which is PR expressed since steroid hormone regulation can be mediated also through epithelial-stromal cross talk in the endometrium [57]. Also P can elicit a variety of rapid signalling events, independently of a direct transcriptional regulation or even in the absence of its cognate nuclear receptors [58] which may modulate gene expression. The molecular mechanism behind the defect in P-regulated gene networks in the endometrium of women with repeated embryo implantation failure is yet to be determined.

Conclusions

We conclude that some cases of repeated implantation failure could be associated with an aberrant gene expression profile, particularly of transcripts related to the immune function and complement activation. Compromised P signaling might be the underlying mechanism for such endometrial gene expression deregulation in women with repeated implantation failure. Future research should focus on determining the causes of incomplete P signalling in the endometrium from these women.

Acknowledgements

We acknowledge to all volunteer women participating in the present study for their generous contribution. Also we acknowledge Dr. Fernando Gabler for dating the endometrial samples, Dr. H. Koistinen for providing the glycodelin antibody and Felipe Argandona for excellent technical assistance. This work was supported by FONDECYT 11100443 / 1140614 and FONDAP 15010006.

Abbreviations

DAVID

Database for annotation visualization and integrated discovery

E2

Estradiol

ELS

Expression level score

GATHER

Gene annotation tool to help explain relationships

IHC

Immunohistochemistry

mAdb

National cancer institute’s microarrays data base webtool

P

Progesterone

PAEP

Progestagen-associated endometrial protein

PCA

Principal component analysis

Pgr

Progesterone receptor gene

PR

Progesterone receptor

PR-A/B

Progesterone receptor isoforms A and B

PR-B

Progesterone receptor isoform B

PREs

Progesterone-response elements

PROGINS

Alu insertion in intron G of the progesterone receptor gene

RFLP

Restriction fragment length polymorphism

RT-PCR

Reverse transcription coupled to polymerase chain reaction

Sp1

Specificity Protein 1..

Footnotes

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AT conceived the study, participated in its design, carried out the microarrays and bioinformatic analyses and helped to draft the manuscript. PF and JB participated in PROGINS detection. J.C.M participated in PROGINS detection, data analysis and interpretation. D.J.M. participated in microarrays analysis. HBC conceived the study, participated in its design, data interpretation and helped to draft the manuscript. All authors read and approved the final manuscript.

Contributor Information

Alejandro Tapia-Pizarro, Email: atapiap@gmail.com.

Paula Figueroa, Email: dromiciops@gmail.com.

Julio Brito, Email: bioprofesor21@gmail.com.

Juan Carlos Marín, Email: jcmarin@ubiobio.cl.

David J Munroe, Email: munroed2@mail.nih.gov.

Horacio B Croxatto, Email: horacio.croxatto@unab.cl.

References

  • 1.O’Malley BW, Tsai MJ. Molecular pathways of steroid receptor action. Biol Reprod. 1992;46:163–167. doi: 10.1095/biolreprod46.2.163. [DOI] [PubMed] [Google Scholar]
  • 2.Gellersen B, Brosens IA, Brosens JJ. Decidualization of the human endometrium: mechanisms, functions, and clinical perspectives. Semin Reprod Med. 2007;25:445–453. doi: 10.1055/s-2007-991042. [DOI] [PubMed] [Google Scholar]
  • 3.Beato M. Gene regulation by steroid hormones. Cell. 1989;56:335–344. doi: 10.1016/0092-8674(89)90237-7. [DOI] [PubMed] [Google Scholar]
  • 4.Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA, Giudice LC. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148:3814–3826. doi: 10.1210/en.2006-1692. [DOI] [PubMed] [Google Scholar]
  • 5.Hapangama DK, Critchley HO, Henderson TA, Baird DT. Mifepristone-induced vaginal bleeding is associated with increased immunostaining for cyclooxygenase-2 and decrease in prostaglandin dehydrogenase in luteal phase endometrium. J Clin Endocrinol Metab. 2002;87:5229–5234. doi: 10.1210/jc.2002-020429. [DOI] [PubMed] [Google Scholar]
  • 6.Danielsson KG, Marions L, Bygdeman M. Effects of mifepristone on endometrial receptivity. Steroids. 2003;68:1069–1075. doi: 10.1016/S0039-128X(03)00131-4. [DOI] [PubMed] [Google Scholar]
  • 7.Catalano RD, Critchley HO, Heikinheimo O, Baird DT, Hapangama D, Sherwin JR, Charnock-Jones DS, Smith SK, Sharkey AM. Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007;13:641–654. doi: 10.1093/molehr/gam021. [DOI] [PubMed] [Google Scholar]
  • 8.Horcajadas JA, Pellicer A, Simon C. Wide genomic analysis of human endometrial receptivity: new times, new opportunities. Hum Reprod Update. 2007;13:77–86. doi: 10.1093/humupd/dml046. [DOI] [PubMed] [Google Scholar]
  • 9.Ruiz-Alonso M, Blesa D, Simon C. The genomics of the human endometrium. Biochim Biophys Acta. 1822;2012:1931–1942. doi: 10.1016/j.bbadis.2012.05.004. [DOI] [PubMed] [Google Scholar]
  • 10.Haouzi D, Dechaud H, Assou S, De Vos J, Hamamah S. Insights into human endometrial receptivity from transcriptomic and proteomic data. Reprod Biomed Online. 2012;24:23–34. doi: 10.1016/j.rbmo.2011.09.009. [DOI] [PubMed] [Google Scholar]
  • 11.Tapia A, Vilos C, Marin JC, Croxatto HB, Devoto L. Bioinformatic detection of E47, E2F1 and SREBP1 transcription factors as potential regulators of genes associated to acquisition of endometrial receptivity. Reprod Biol Endocrinol. 2011;9:14. doi: 10.1186/1477-7827-9-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Tapia A, Gangi LM, Zegers-Hochschild F, Balmaceda J, Pommer R, Trejo L, Pacheco IM, Salvatierra AM, Henriquez S, Quezada M, Vargas M, Ríos M, Munroe DJ, Croxatto HB, Velasquez L. Differences in the endometrial transcript profile during the receptive period between women who were refractory to implantation and those who achieved pregnancy. Hum Reprod. 2008;23:340–351. doi: 10.1093/humrep/dem319. [DOI] [PubMed] [Google Scholar]
  • 13.Damario MA, Lesnick TG, Lessey BA, Kowalik A, Mandelin E, Seppala M, Rosenwaks Z. Endometrial markers of uterine receptivity utilizing the donor oocyte model. Hum Reprod. 2001;16:1893–1899. doi: 10.1093/humrep/16.9.1893. [DOI] [PubMed] [Google Scholar]
  • 14.Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975;122:262–263. doi: 10.1016/s0002-9378(16)33500-1. [DOI] [PubMed] [Google Scholar]
  • 15.Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Statist Soc Ser B (Method) 1995;57:289–300. [Google Scholar]
  • 16.Joliffe IT, Morgan BJ. Principal component analysis and exploratory factor analysis. Stat Methods Med Res. 1992;1:69–95. doi: 10.1177/096228029200100105. [DOI] [PubMed] [Google Scholar]
  • 17.Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3. doi: 10.1186/gb-2003-4-5-p3. [DOI] [PubMed] [Google Scholar]
  • 18.Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics. 2006;22:2926–2933. doi: 10.1093/bioinformatics/btl483. [DOI] [PubMed] [Google Scholar]
  • 19.Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006;34:D354–357. doi: 10.1093/nar/gkj102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. Gene Ontology Consortium Nat Genet. 2000;25:25–29. doi: 10.1038/75556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Gonzalez-Ramos R, Rocco J, Rojas C, Sovino H, Poch A, Kohen P, Alvarado-Diaz C, Devoto L. Physiologic activation of nuclear factor kappa-B in the endometrium during the menstrual cycle is altered in endometriosis patients. Fertil Steril. 2012;97:645–651. doi: 10.1016/j.fertnstert.2011.12.006. [DOI] [PubMed] [Google Scholar]
  • 22.Koistinen H, Koistinen R, Dell A, Morris HR, Easton RL, Patankar MS, Oehninger S, Clark GF, Seppala M. Glycodelin from seminal plasma is a differentially glycosylated form of contraceptive glycodelin-A. Mol Hum Reprod. 1996;2:759–765. doi: 10.1093/molehr/2.10.759. [DOI] [PubMed] [Google Scholar]
  • 23.Pisarska MD, Carson SA, Casson PR, Tong X, Buster JE, Kieback DG. A mutated progesterone receptor allele is more prevalent in unexplained infertility. Fertil Steril. 2003;80:651–653. doi: 10.1016/S0015-0282(03)00755-6. [DOI] [PubMed] [Google Scholar]
  • 24.Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, Taylor RN, Lessey BA, Giudice LC. Global gene profiling in human endometrium during the window of implantation. Endocrinology. 2002;143:2119–2138. doi: 10.1210/endo.143.6.8885. [DOI] [PubMed] [Google Scholar]
  • 25.Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Teirney R, Phillips SC, Smith SK. Determination of the transcript profile of human endometrium. Mol Hum Reprod. 2003;9:19–33. doi: 10.1093/molehr/gag004. [DOI] [PubMed] [Google Scholar]
  • 26.Carson DD, Lagow E, Thathiah A, Al-Shami R, Farach-Carson MC, Vernon M, Yuan L, Fritz MA, Lessey B. Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening. Mol Hum Reprod. 2002;8:871–879. doi: 10.1093/molehr/8.9.871. [DOI] [PubMed] [Google Scholar]
  • 27.Riesewijk A, Martin J, van Os R, Horcajadas JA, Polman J, Pellicer A, Mosselman S, Simon C. Gene expression profiling of human endometrial receptivity on days LH + 2 versus LH + 7 by microarray technology. Mol Hum Reprod. 2003;9:253–264. doi: 10.1093/molehr/gag037. [DOI] [PubMed] [Google Scholar]
  • 28.Mirkin S, Arslan M, Churikov D, Corica A, Diaz JI, Williams S, Bocca S, Oehninger S. In search of candidate genes critically expressed in the human endometrium during the window of implantation. Hum Reprod. 2005;20:2104–2117. doi: 10.1093/humrep/dei051. [DOI] [PubMed] [Google Scholar]
  • 29.Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA, Nayak NR, Giudice LC. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology. 2006;147:1097–1121. doi: 10.1210/en.2005-1076. [DOI] [PubMed] [Google Scholar]
  • 30.Ace CI, Okulicz WC. Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase. Reprod Biol Endocrinol. 2004;2:54. doi: 10.1186/1477-7827-2-54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Haouzi D, Mahmoud K, Fourar M, Bendhaou K, Dechaud H, De Vos J, Reme T, Dewailly D, Hamamah S. Identification of new biomarkers of human endometrial receptivity in the natural cycle. Hum Reprod. 2009;24:198–205. doi: 10.1093/humrep/den360. [DOI] [PubMed] [Google Scholar]
  • 32.Diaz-Gimeno P, Horcajadas JA, Martinez-Conejero JA, Esteban FJ, Alama P, Pellicer A, Simon C. A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature. Fertil Steril. 2011;95:50–60. doi: 10.1016/j.fertnstert.2010.04.063. [DOI] [PubMed] [Google Scholar]
  • 33.Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, Innes J, Julie Kim J. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248:94–103. doi: 10.1016/j.mce.2005.11.041. [DOI] [PubMed] [Google Scholar]
  • 34.Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000;85:2897–2902. doi: 10.1210/jcem.85.8.6739. [DOI] [PubMed] [Google Scholar]
  • 35.Coulam CB, Jeyendran RS, Roussev R. Association of progesterone receptor polymorphisms with recurrent implantation failure after in vitro fertilization and embryo transfer. J Assist Reprod Genet. 2008;25:119–122. doi: 10.1007/s10815-008-9210-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Seppala M, Bohn H, Tatarinov Y. Glycodelins. Tumour Biol. 1998;19:213–220. doi: 10.1159/000030009. [DOI] [PubMed] [Google Scholar]
  • 37.Seppala M, Taylor RN, Koistinen H, Koistinen R, Milgrom E. Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr Rev. 2002;23:401–430. doi: 10.1210/er.2001-0026. [DOI] [PubMed] [Google Scholar]
  • 38.Bell SC, Hales MW, Patel S, Kirwan PH, Drife JO. Protein synthesis and secretion by the human endometrium and decidua during early pregnancy. Br J Obstet Gynaecol. 1985;92:793–803. doi: 10.1111/j.1471-0528.1985.tb03048.x. [DOI] [PubMed] [Google Scholar]
  • 39.Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, Osteen K, Lessey BA, Giudice LC. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology. 2003;144:2870–2881. doi: 10.1210/en.2003-0043. [DOI] [PubMed] [Google Scholar]
  • 40.Mackenna A, Li TC, Dalton C, Bolton A, Cooke I. Placental protein 14 levels in uterine flushing and plasma of women with unexplained infertility. Fertil Steril. 1993;59:577–582. doi: 10.1016/s0015-0282(16)55803-8. [DOI] [PubMed] [Google Scholar]
  • 41.Seppala M, Koistinen H, Koistinen R, Chiu PC, Yeung WS. Glycosylation related actions of glycodelin: gamete, cumulus cell, immune cell and clinical associations. Hum Reprod Update. 2007;13:275–287. doi: 10.1093/humupd/dmm004. [DOI] [PubMed] [Google Scholar]
  • 42.Taylor RN, Vigne JL, Zhang P, Hoang P, Lebovic DI, Mueller MD. Effects of progestins and relaxin on glycodelin gene expression in human endometrial cells. Am J Obstet Gynecol. 2000;182:841–847. doi: 10.1016/S0002-9378(00)70333-4. [DOI] [PubMed] [Google Scholar]
  • 43.Taylor RN, Savouret JF, Vaisse C, Vigne JL, Ryan I, Hornung D, Seppala M, Milgrom E. Promegestone (R5020) and mifepristone (RU486) both function as progestational agonists of human glycodelin gene expression in isolated human epithelial cells. J Clin Endocrinol Metab. 1998;83:4006–4012. doi: 10.1210/jcem.83.11.5214. [DOI] [PubMed] [Google Scholar]
  • 44.Vaisse C, Atger M, Potier B, Milgrom E. Human placental protein 14 gene: sequence and characterization of a short duplication. DNA Cell Biol. 1990;9:401–413. doi: 10.1089/dna.1990.9.401. [DOI] [PubMed] [Google Scholar]
  • 45.Gao J, Mazella J, Seppala M, Tseng L. Ligand activated hPR modulates the glycodelin promoter activity through the Sp1 sites in human endometrial adenocarcinoma cells. Mol Cell Endocrinol. 2001;176:97–102. doi: 10.1016/S0303-7207(01)00450-6. [DOI] [PubMed] [Google Scholar]
  • 46.Aghajanova L, Velarde MC, Giudice LC. Altered gene expression profiling in endometrium: evidence for progesterone resistance. Semin Reprod Med. 2010;28:51–58. doi: 10.1055/s-0029-1242994. [DOI] [PubMed] [Google Scholar]
  • 47.Taylor HS, Bagot C, Kardana A, Olive D, Arici A. HOX gene expression is altered in the endometrium of women with endometriosis. Hum Reprod. 1999;14:1328–1331. doi: 10.1093/humrep/14.5.1328. [DOI] [PubMed] [Google Scholar]
  • 48.Hirota Y, Tranguch S, Daikoku T, Hasegawa A, Osuga Y, Taketani Y, Dey SK. Deficiency of immunophilin FKBP52 promotes endometriosis. Am J Pathol. 2008;173:1747–1757. doi: 10.2353/ajpath.2008.080527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Aghajanova L, Velarde MC, Giudice LC. The progesterone receptor coactivator Hic-5 is involved in the pathophysiology of endometriosis. Endocrinology. 2009;150:3863–3870. doi: 10.1210/en.2009-0008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Caballero V, Ruiz R, Sainz JA, Cruz M, Lopez-Nevot MA, Galan JJ, Real LM, de Castro F, Lopez-Villaverde V, Ruiz A. Preliminary molecular genetic analysis of the Receptor Interacting Protein 140 (RIP140) in women affected by endometriosis. J Exp Clin Assist Reprod. 2005;2:11. doi: 10.1186/1743-1050-2-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Suzuki A, Horiuchi A, Oka K, Miyamoto T, Kashima H, Shiozawa T. Immunohistochemical detection of steroid receptor cofactors in ovarian endometriosis: involvement of down-regulated SRC-1 expression in the limited growth activity of the endometriotic epithelium. Virchows Arch. 2010;456:433–441. doi: 10.1007/s00428-010-0884-x. [DOI] [PubMed] [Google Scholar]
  • 52.Kim JJ, Taylor HS, Lu Z, Ladhani O, Hastings JM, Jackson KS, Wu Y, Guo SW, Fazleabas AT. Altered expression of HOXA10 in endometriosis: potential role in decidualization. Mol Hum Reprod. 2007;13:323–332. doi: 10.1093/molehr/gam005. [DOI] [PubMed] [Google Scholar]
  • 53.Lee B, Du H, Taylor HS. Experimental murine endometriosis induces DNA methylation and altered gene expression in eutopic endometrium. Biol Reprod. 2009;80:79–85. doi: 10.1095/biolreprod.108.070391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Shazand K, Baban S, Prive C, Malette B, Croteau P, Lagace M, Racine JB, Hugo P. FOXO1 and c-jun transcription factors mRNA are modulated in endometriosis. Mol Hum Reprod. 2004;10:871–877. doi: 10.1093/molehr/gah119. [DOI] [PubMed] [Google Scholar]
  • 55.Wu Y, Halverson G, Basir Z, Strawn E, Yan P, Guo SW. Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol. 2005;193:371–380. doi: 10.1016/j.ajog.2005.01.034. [DOI] [PubMed] [Google Scholar]
  • 56.Yang S, Fang Z, Suzuki T, Sasano H, Zhou J, Gurates B, Tamura M, Ferrer K, Bulun S. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins (C/EBPs): decreased C/EBPbeta in endometriosis is associated with overexpression of aromatase. J Clin Endocrinol Metab. 2002;87:2336–2345. doi: 10.1210/jcem.87.5.8486. [DOI] [PubMed] [Google Scholar]
  • 57.Cunha GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol. 2004;67:417–434. doi: 10.1679/aohc.67.417. [DOI] [PubMed] [Google Scholar]
  • 58.Gellersen B, Fernandes MS, Brosens JJ. Non-genomic progesterone actions in female reproduction. Hum Reprod Update. 2009;15:119–138. doi: 10.1093/humupd/dmn044. [DOI] [PubMed] [Google Scholar]

Articles from Reproductive Biology and Endocrinology : RB&E are provided here courtesy of BMC

RESOURCES